- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Pharma Marketers Guide to Medication Adherence
Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Patient Adherence and Access Summit
June 17–18, 2014
Philadelphia, Pennsylvania
RELATED
- Changing the DNA of Pharma Patient Adherence Programs
- Why Patient Adherence is a Policy Issue
- The First and Last Word on Medication Adherence: Keep Trying
MORE IN PATIENT ADHERENCE & ACCESS
How can this knowledge help? Many recent industry programs have achieved only a 1-3% increase in adherence, and ROIs of less than 3. To realize results of 20%+ and ROIs above 3/1, critical appraisal of the past and direction to probable futures are needed (several pharma companies have achieved 38%+ lifts in persistence with this new knowledge). This experience can provide the pharma marketer with a needed guide to planning and program implementation.
At this month’s Center for Business Intelligence (CBI) Patient Adherence and Support Summit (April 29-30), in Philadelphia, brand directors and marketers will have a unique opportunity to hear senior VP’s, consultants and academic researchers provide their perspectives on what we know and need to target in 2013.
The event will begin with a keynote panel speaking about the changing DNA of patient adherence programs. Presenters will be VP’s and Senior Directors from Eli Lilly, GSK, Sanofi, and Shire.
For the first time since the inception of CBI’s Strategic Patient Adherence (SPA) Awards, there will be a look back at where the winning programs are today. This panel will follow presentation of an Adherence Roadmap by Dr. William Shrank, a prolific adherence researcher.
Tuesday will include a unique opportunity to hear one of the world’s most cited industry researchers, Merck’s Dr. Colleen McHorney. Dr. McHorney will be reviewing the history of adherence research and how the paradigm has shifted.
For more information on this event, now in its 12th year, go to:
http://www.cbinet.com/conference/pc13116#.UVx-3KLvHE0
For more information on this article, you can reach Grant Corbett, Principal, Behavior Change Solutions, Inc. at grant.corbett@behavior-change-solutions.com.
See also: http://blog.pharmexec.com/2013/03/12/changing-the-dna-of-pharma-patient-adherence-programs/
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
